Enalapril prevents cardiac immune-mediated damage and exerts anti- Trypanosoma cruzi activity during acute phase of experimental Chagas disease.
Nenhuma Miniatura disponível
Data
2010
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Chagas heart disease (CHD), caused by Trypanosoma cruzi
infection, is a significant cause of morbidity and mortality
in South and Central America. Enalapril, an angiotensin
converting enzyme (ACE) inhibitor, is an important drug
used to ameliorate heart functional capacity and its remodelling
in individuals presenting CHD. In this study, we evaluated
the effects of enalapril on systemic and cardiac immune
response during experimental acute CHD. C57BL ⁄ 6 mice
infected with 50 trypomastigote forms of T. cruzi (Colombian
strain) were treated daily with enalapril (25 mg ⁄ kg)
and, after 30 days, a reduction in seric levels of IFNgamma,
TNF-alpha, CCL5⁄RANTES and nitric oxide, but
not in that of IL-10, was detected. This imbalance of cytokines
reflects in a reduction of heart mononuclear infiltration
and in an increasing of cardiac mast cells. Enalapril
also presents a new and interesting in vitro and in vivo anti-
T. cruzi activity probably acting on parasite oxidative pathway
via cytochrome-P450. Our data show that enalapril
exerts an important anti-T. cruzi and anti-inflammatory
activity during acute CHD reducing inflammatory cells and,
possibly, preventing fibrotic process in the chronic phase.
Nevertheless, further studies are still necessary to clarify the
mechanisms by which this drug is acting on the parasites
and on the immune pathways.
Descrição
Palavras-chave
Cytokines, Heart inflammation
Citação
COSTA, G. P. et al. Enalapril prevents cardiac immune-mediated damage and exerts anti-Trypanosoma cruzi activity during acute phase of experimental Chagas disease. Parasite Immunology, v. 32, p. 202-208, 2010. Disponível em: <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3024.2009.01179.x/abstract>. Acesso em: 19 fev. 2017.